MedWatch

Orphazyme falls back into old habits – delays report

On Monday, the biotech company said there would be no new financial report on Tuesday, the day one was scheduled to be released.

Old habits die hard.

With less than a day to go before the biotech company was meant to publish its half-year report, Orphazyme announced Monday that it would not be releasing its half-year report the following day, today, when it was supposed to go public.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs